<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950689</url>
  </required_header>
  <id_info>
    <org_study_id>CFTSp032, 11_DOG08_53</org_study_id>
    <nct_id>NCT01950689</nct_id>
  </id_info>
  <brief_title>NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)</brief_title>
  <acronym>NIMRAD</acronym>
  <official_title>A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Christie NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether adding Nimorazole to standard radiotherapy&#xD;
      benefits patients with locally advanced head and neck squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2014</start_date>
  <completion_date type="Actual">January 7, 2021</completion_date>
  <primary_completion_date type="Actual">January 7, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Locoregional Control in patients with more hypoxic tumours (the enriched population)</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>To examine whether patients with locally advanced head and neck squamous cell carcinoma unsuitable for either cisplatin chemotherapy or monoclonal antibody therapy benefit from the addition of nimorazole to standard definitive radiotherapy in terms of increased locoregional control without additional serious toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (enriched sub-group)</measure>
    <time_frame>Date of death for patient, month 60.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-specific survival (enriched sub-group)</measure>
    <time_frame>follow up month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (enriched sub-group)</measure>
    <time_frame>follow up month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of loco-regional failure</measure>
    <time_frame>follow up month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity (all patients)</measure>
    <time_frame>baseline, week 1, 2, 3, 4, 5, 6, follow up month 1.5 and 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoxia signature prediction of nimorazole benefit (all patients)</measure>
    <time_frame>screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (enriched sub-group)</measure>
    <time_frame>baseline, week 6, month 6, 12, 18, 24, 36 of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity (all patients)</measure>
    <time_frame>baseline, follow up month 6, 12, 18, 24, 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">338</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given in parallel with radiotherapy for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nimorazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nimorazole given in parallel with radiotherapy for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimorazole</intervention_name>
    <arm_group_label>Nimorazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Nimorazole</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed (newly diagnosed/ not recurrent) head and neck squamous cell&#xD;
             carcinoma; all primary subsites EXCEPT nasal cavity, oral cavity, nasopharynx and&#xD;
             paranasal sinus (i.e. oropharynx, hypopharynx, larynx are allowed)&#xD;
&#xD;
          -  Stage T3/T4 N0; any node +ve case including T1 node +ve; T2N0 base of&#xD;
             tongue/hypopharynx&#xD;
&#xD;
          -  Patients suitable for definitive radiotherapy. Block dissections may be performed&#xD;
             pre-RT for N2/N3 disease&#xD;
&#xD;
          -  WHO status 0-2&#xD;
&#xD;
          -  Patient fit and able to undergo RT with nimorazole and be expected to complete&#xD;
             treatment&#xD;
&#xD;
          -  Absence of another disease or previous malignancy which is likely to interfere with&#xD;
             the treatment or assessment of response&#xD;
&#xD;
          -  No evidence of distant metastases (M0)&#xD;
&#xD;
          -  Unable to tolerate/unlikely to benefit from platinum chemotherapy or monoclonal&#xD;
             antibody therapy&#xD;
&#xD;
          -  Women must be postmenopausal (no menstrual period for a minimum of 1 year) or have a&#xD;
             negative serum pregnancy test on entry in the study (even if surgically sterilised)&#xD;
             and be using an adequate contraception method. This must be continued for 1 week after&#xD;
             completion of nimorazole, unless child bearing potential has been terminated by&#xD;
             surgery/radical radiotherapy&#xD;
&#xD;
          -  Men must be willing to use an adequate method of contraception during treatment and&#xD;
             until 1 week after nimorazole&#xD;
&#xD;
          -  Greater than 18 years of age; no upper age limit&#xD;
&#xD;
          -  Available for follow up within the United Kingdom&#xD;
&#xD;
          -  Adequate renal and liver function - absolute neutrophil count &gt;=1.5 x 109/L,&#xD;
             creatinine &lt;=2x ULN, platelets &gt; 100x109/L, total bilirubin &lt;=2 x ULN, AST or ALT &lt;3 x&#xD;
             ULN&#xD;
&#xD;
          -  The capacity to understand the patient information sheet and the ability to provide&#xD;
             written informed consent&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with T1N0 tumours or those within the nasopharynx, nasal cavity or sinus,&#xD;
             oral cavity; T2No larynx and tonsil; unknown primary cancer.&#xD;
&#xD;
          -  Any prior chemotherapy in the last 6 months or RT within the planned radiation field&#xD;
&#xD;
          -  Presence of any life threatening illness such as unstable angina or severe chronic&#xD;
             obstructive pulmonary disease&#xD;
&#xD;
          -  Mental disability or patient otherwise unable to give informed consent and/or complete&#xD;
             patient questionnaires&#xD;
&#xD;
          -  Hb &lt;100 g/l (patients with anaemia may be transfused to bring Hb levels to &gt;100 g/l&#xD;
             within 1 week of treatment start. Please repeat Hb following transfusion to confirm&#xD;
             now eligible)&#xD;
&#xD;
          -  Peripheral neurophathy as assessed clinically (CTCAE &gt;=2)&#xD;
&#xD;
          -  Use of any investigational drug within 30 days prior to screening&#xD;
&#xD;
          -  Severe and/or uncontrolled medical disease&#xD;
&#xD;
          -  Any malabsorption syndrome (i.e. partial gastrectomy, small bowel resection, Crohn's&#xD;
             disease or ulcerative colitis)&#xD;
&#xD;
          -  Use of Lithium or Phenobarbitone during the study&#xD;
&#xD;
          -  Patients who are breastfeeding or pregnant&#xD;
&#xD;
          -  Previous malignancy within 5 years (except BCC, in-situ Ca e.g. of the cervix)&#xD;
&#xD;
          -  Previous definitive surgery to primary site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Thomson</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <state>Gloucestershire</state>
        <zip>GL53 7AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology</name>
      <address>
        <city>Bebington</city>
        <state>Merseyside</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James' Hospital</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology centre</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Centre</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The James Cook University Hospital</name>
      <address>
        <city>Middlesborough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <zip>Y031 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Christie NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Yamina Ainaoui</investigator_full_name>
    <investigator_title>Clinical Trials Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimorazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

